Commentary| Volume 45, 102441, October 2020

Brain creatine for predicting clinical course in white matter disorders

Published:August 04, 2020DOI:
      Creatine plays a pivotal role in brain bioenergetics, acting as a temporal and spatial energy buffer, energy transducer, and metabolic regulator. A low cerebral creatine concentration illustrating energy depletion has been routinely observed in various neuropathologies, including cerebrovascular diseases, brain neoplasms, inborn disorders of creatine metabolism, and age-related conditions. (
      • Niedzwiecki MM
      • Walker DI
      • Howell JC
      • et al.
      High-resolution metabolomic profiling of Alzheimer's disease in plasma.
      ) White matter disorders (WMD), however, appear to encounter a different dynamics in brain creatine variation that could be potentially useful in the disease screening and prognosis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Niedzwiecki MM
        • Walker DI
        • Howell JC
        • et al.
        High-resolution metabolomic profiling of Alzheimer's disease in plasma.
        Ann. Clin. Transl. Neurol. 2020; 7: 36-45
        • Kirov II
        • Liu S
        • Tal A
        • et al.
        Proton MR spectroscopy of lesion evolution in multiple sclerosis: Steady-state metabolism and its relationship to conventional imaging.
        Hum. Brain Mapp. 2017; 38: 4047-4063
        • Klauser AM
        • Wiebenga OT
        • Eijlers AJ
        • et al.
        Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
        Mult. Scler. 2018; 24: 491-500
        • van Rappard DF
        • Klauser A
        • Steenweg ME
        • et al.
        Quantitative MR spectroscopic imaging in metachromatic leukodystrophy: value for prognosis and treatment.
        J. Neurol. Neurosurg. Psychiatry. 2018; 89: 105-111
        • Rae CD
        • Bröer S.
        Creatine as a booster for human brain function. How might it work?.
        Neurochem. Int. 2015; 89: 249-259
        • Wiebenga OT
        • Klauser AM
        • Nagtegaal GJ
        • Schoonheim MM
        • Barkhof F
        • Geurts JJ
        • Pouwels PJ
        Longitudinal absolute metabolite quantification of white and gray matter regions in healthy controls using proton MR spectroscopic imaging.
        NMR Biomed. 2014; 27: 304-311
        • Govindaraju V
        • Young K
        • Maudsley AA
        Proton NMR chemical shifts and coupling constants for brain metabolites.
        NMR Biomed. 2000; 13: 129-153
        • Hattingen E
        • Magerkurth J
        • Pilatus U
        • Hübers A
        • Wahl M
        • Ziemann U
        Combined (1)H and (31)P spectroscopy provides new insights into the pathobiochemistry of brain damage in multiple sclerosis.
        NMR Biomed. 2011; 24: 536-546
        • Kauv P
        • Ayache SS
        • Créange A
        • Chalah MA
        • Lefaucheur JP
        • Hodel J
        • Brugières P
        Adenosine triphosphate metabolism measured by phosphorus magnetic resonance spectroscopy: a potential biomarker for multiple sclerosis severity.
        Eur. Neurol. 2017; 77: 316-321
        • Cambron M
        • Reynders T
        • Debruyne J
        • Reyngoudt H
        • Ribbens A
        • Achten E
        • Laureys G
        Targeting phosphocreatine metabolism in relapsing–remitting multiple sclerosis: evaluation with brain MRI, 1 H and 31 P MRS, and clinical and cognitive testing.
        J. Neurol. 2018; 265: 2614-2624
        • Hoch SE
        • Kirov II
        • Tal A
        When are metabolic ratios superior to absolute quantification? A statistical analysis.
        NMR Biomed. 2017; 30: e3710
        • Faissner S
        • Gold R
        Progressive multiple sclerosis: latest therapeutic developments and future directions.
        Ther. Adv. Neurol. Disord. 2019; 121756286419878323